Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07031323 · ClinicalTrials.gov registry record · NA
OnTrackCF: Engagement, Feasibility, and Acceptability Study
A NA study of Cystic Fibrosis (CF) and Cystic Fibrosis - Complete, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT07031323: Recruiting NA study of Cystic Fibrosis (CF) and Cystic Fibrosis - Complete, sponsored by Boston Children's Hospital.
NCT07031323 is a NA study of Cystic Fibrosis (CF) and Cystic Fibrosis - Complete that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 60 participants, below the 137-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (56% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07031323, a NA study of Cystic Fibrosis (CF) and Cystic Fibrosis - Complete, is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multi-site, nonrandomized study using mixed methods approach to evaluate the feasibility, acceptability, and user engagement of OnTrackCF for adults with Cystic Fibrosis (AWCF).
Primary Outcome
By the last round of testing, the System Usability Survey (SUS) will have a median score of 75%.
Conditions Studied
Interventions
- BEHAVIORAL OnTrackCF
Study Locations (3)
Alabama
- University of Alabama-Birmingham - Birmingham
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-11-20 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT07031323 shows while recruiting
NCT07031323 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 137-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (56% lower).
The record links to 2 conditions, with Cystic Fibrosis (CF) appearing as the primary indexed condition, and to 1 intervention - of which OnTrackCF is the first listed.
NCT07031323 reports a single indexed study location in Alabama, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07031323 about?
NCT07031323 is a clinical study titled "OnTrackCF: Engagement, Feasibility, and Acceptability Study". This is a multi-site, nonrandomized study using mixed methods approach to evaluate the feasibility, acceptability, and user engagement of OnTrackCF for adults with Cystic Fibrosis (AWCF).
What is the current status of trial NCT07031323?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-11-20. Estimated completion is 2026-12.
What conditions does trial NCT07031323 study?
This clinical trial studies the following conditions: Cystic Fibrosis (CF), Cystic Fibrosis - Complete.
What interventions are being tested in trial NCT07031323?
The interventions under investigation include: OnTrackCF (BEHAVIORAL).
Who is sponsoring clinical trial NCT07031323?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07031323 being conducted?
This trial has 3 study locations across Alabama, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis (CF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07031323's enrollment target sits among peer trials
60 11th of 14 higher than 3 of 14 other Cystic Fibrosis (CF) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis (CF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
ACT With CF Self-Help Toolkit
RECRUITING · NA
-
CGM Dynamic Index for Predicting Prediabetes in Cystic Fibrosis
RECRUITING · NA
-
CF Wellness Program
RECRUITING · NA
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
-
Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI